*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Recursion Pharmaceuticals, with its market cap standing at approximately $2.63 billion, is poised for its upcoming earnings release on November 5, 2025. The company's focus on leveraging AI for drug discovery has positioned it as a notable player in the biotech sector, despite the absence of recent news. Analysts are anticipating an EPS of $0.00, aligning with the whisper number, which suggests that expectations are tempered, likely due to the company's reinvestment strategy in research and development. Revenue is projected to reach $16.95 million, reflecting Recursion's ongoing efforts to translate its innovative platform into tangible financial results. As the market awaits the earnings announcement, investors will be keen to see how Recursion's strategic initiatives are progressing and whether they can sustain momentum in a competitive landscape.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.
Website: https://www.recursion.com
Average Sentiment Score:
Overall Sentiment: